<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38444741</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2206-7418</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Nanotheranostics</Title><ISOAbbreviation>Nanotheranostics</ISOAbbreviation></Journal><ArticleTitle>Recurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response.</ArticleTitle><Pagination><StartPage>247</StartPage><EndPage>269</EndPage><MedlinePgn>247-269</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/ntno.91910</ELocationID><Abstract><AbstractText>The post-pandemic era following the global spread of the SARS-CoV-2 virus has brought about persistent concerns regarding recurring coinfections. While significant strides in genome mapping, diagnostics, and vaccine development have controlled the pandemic and reduced fatalities, ongoing virus mutations necessitate a deeper exploration of the interplay between SARS-CoV-2 mutations and the host's immune response. Various vaccines, including RNA-based ones like Pfizer and Moderna, viral vector vaccines like Johnson &amp; Johnson and AstraZeneca, and protein subunit vaccines like Novavax, have played critical roles in mitigating the impact of COVID-19. Understanding their strengths and limitations is crucial for tailoring future vaccines to specific variants and individual needs. The intricate relationship between SARS-CoV-2 mutations and the immune response remains a focus of intense research, providing insights into personalized treatment strategies and long-term effects like long-COVID. This article offers an overview of the post-pandemic landscape, highlighting emerging variants, summarizing vaccine platforms, and delving into immunological responses and the phenomenon of long-COVID. By presenting clinical findings, it aims to contribute to the ongoing understanding of COVID-19's progression in the aftermath of the pandemic.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Ashmit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Divyasampark iHub Roorkee for Devices Materials and Technology Foundation, Indian Institute of Technology Roorkee, Uttarakhand, 247667, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Samrat Ashok Technological Institute, Vidisha, Madhya Pradesh, 464001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manojkumar</LastName><ForeName>Anjali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, College of Science, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhasmana</LastName><ForeName>Anupam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathi</LastName><ForeName>Manish K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaggi</LastName><ForeName>Meena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauhan</LastName><ForeName>Subhash C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauhan</LastName><ForeName>Deepak S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de Pharmacie, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al H3C 3J7, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, IWK Research Center, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yallapu</LastName><ForeName>Murali M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Nanotheranostics</MedlineTA><NlmUniqueID>101698994</NlmUniqueID><ISSNLinking>2206-7418</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000096202">Protein Subunit Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000096202" MajorTopicYN="N">Protein Subunit Vaccines</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>6</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38444741</ArticleId><ArticleId IdType="pmc">PMC10911975</ArticleId><ArticleId IdType="doi">10.7150/ntno.91910</ArticleId><ArticleId IdType="pii">ntnov08p0247</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. Jama. 2020;323(20):2085&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160748</ArticleId><ArticleId IdType="pubmed">32293646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B. et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020;285:198005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7213959</ArticleId><ArticleId IdType="pubmed">32408156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020;92(9):1549&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228290</ArticleId><ArticleId IdType="pubmed">32196707</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255350</ArticleId><ArticleId IdType="pubmed">32473235</ArticleId></ArticleIdList></Reference><Reference><Citation>Day AT, Sher DJ, Lee RC, Truelson JM, Myers LL, Sumer BD. et al. Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks. Oral Oncol. 2020 Jun;105:104684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136871</ArticleId><ArticleId IdType="pubmed">32330858</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020;43:1027&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195612</ArticleId><ArticleId IdType="pubmed">32361826</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennison Himmelfarb CR, Baptiste D. Coronavirus Disease (COVID-19) J Cardiovasc Nurs. 2020;35(4):318&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236854</ArticleId><ArticleId IdType="pubmed">32384299</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS. et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC. et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Against COVID-19. Post-Acute Care Study Group: for the Gemelli Against CCOVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020. 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact, 38 ECLINICALMEDICINE at 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC. et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Cheng L, Jiang Y, Zhu S. Examining Bayesian network modeling in identification of dangerous driving behavior. PLoS One. 2021;16(8):e0252484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363010</ArticleId><ArticleId IdType="pubmed">34388171</ArticleId></ArticleIdList></Reference><Reference><Citation>Diseases. NC for I and RD (U. S). D of V, editor. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [Internet]. Atlanta, GA; (Coronavirus Disease. 2019. (CoVID-19)). Available from: https://stacks.cdc.gov/view/cdc/89980.</Citation></Reference><Reference><Citation>Long-term effects of COVID-19 (long COVID) - NHS.</Citation></Reference><Reference><Citation>Greenhalgh T, Knight M, Buxton M, Husain L. Management of post-acute covid-19 in primary care. bmj. 2020. 370.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y miao, Shang Y min, Song W bin, Li Q quan, Xie H, Xu Q fu. et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228727</ArticleId><ArticleId IdType="pubmed">32422178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) Respir Med. 2020;167:105941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154502</ArticleId><ArticleId IdType="pubmed">32421537</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirza FN, Malik AA, Omer SB, Sethi A. Dermatologic manifestations of COVID-19: a comprehensive systematic review. Int J Dermatol. 2021 Apr 1;60(4):418&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">33141443</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xee;rjaliu RE, Deacu M, Gherghi&#x219;an I, Marghescu A &#x218;tefania, Enciu M, B&#x103;lt&#x103;&#x21b;escu GI, Clinicopathological Outlines of Post-COVID-19 Pulmonary Fibrosis Compared with Idiopathic Pulmonary Fibrosis. Biomedicines. 2023. 11(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10296314</ArticleId><ArticleId IdType="pubmed">37371834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sriramula S, Theobald D, Parekh RU, Akula SM, O'Rourke DP, Eells JB. Emerging Role of Kinin B1 Receptor in Persistent Neuroinflammation and Neuropsychiatric Symptoms in Mice Following Recovery from SARS-CoV-2 Infection. Cells. 2023. 12(16)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10453171</ArticleId><ArticleId IdType="pubmed">37626917</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Mihailidou AS, Bolanos CR, Ka MM, Valbuena-L&#xf3;pez S, Rolf A, Cardiac Involvement Due to COVID-19: Insights from Imaging and Histopathology. Eur Cardiol Rev 202318e58 [Internet]. 2023; Available from: https://doi.org/10.15420/ecr. 2023. 02.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10628999</ArticleId><ArticleId IdType="pubmed">37942208</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambella A, Barreca A, Biancone L, Roccatello D, Peruzzi L, Besso L, Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service. Biomolecules. 2022. 12(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8961620</ArticleId><ArticleId IdType="pubmed">35204798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. bmj. 2021. 372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R. et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med. 2021;21(1):e63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5(11):1265&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, Bluemke DA, L&#xfc;scher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022;43(11):1157&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD. et al. Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. Cardiovasc Imaging. 2021;14(11):2155&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8105493</ArticleId><ArticleId IdType="pubmed">33975819</ArticleId></ArticleIdList></Reference><Reference><Citation>Moody WE, Liu B, Mahmoud-Elsayed HM, Senior J, Lalla SS, Khan-Kheil AM. et al. Persisting adverse ventricular remodeling in COVID-19 survivors: a longitudinal echocardiographic study. J Am Soc Echocardiogr. 2021;34(5):562&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008825</ArticleId><ArticleId IdType="pubmed">33539950</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M. et al. Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing. Chest. 2022;161(1):54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354807</ArticleId><ArticleId IdType="pubmed">34389297</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassar MP, Tunnicliffe EM, Petousi N, Lewandowski AJ, Xie C, Mahmod M. et al. Symptom persistence despite improvement in cardiopulmonary health-insights from longitudinal CMR, CPET and lung function testing post-COVID-19. EClinicalMedicine. 2021;41:101159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8527025</ArticleId><ArticleId IdType="pubmed">34693230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini DM, Brunjes DL, Lala A, Trivieri MG, Contreras JP, Natelson BH. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease. Heart Fail. 2021;9(12):927&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629098</ArticleId><ArticleId IdType="pubmed">34857177</ArticleId></ArticleIdList></Reference><Reference><Citation>Korompoki E, Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. Am J Hematol. 2022;97(1):119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646944</ArticleId><ArticleId IdType="pubmed">34687462</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 &#x201c;long haulers.&#x201d; Ann Clin Transl Neurol. 2021;8(5):1073-85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson-Lane SG, Sutton NR, Chubb H, Yeow RY, Mazzara N, DeMarco K. et al. Race, ethnicity, and 60-day outcomes after hospitalization with COVID-19. J Am Med Dir Assoc. 2021;22(11):2245&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8490827</ArticleId><ArticleId IdType="pubmed">34716006</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolen LT, Mukerji SS, Mejia NI. Post-acute neurological consequences of COVID-19: an unequal burden. Nat Med. 2022;28(1):20&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">35039657</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud M, Thibault C, Le Normand F, Mcdonald EG, Gallix B, Debry C. et al. Clinical outcomes for patients with anosmia 1 year after COVID-19 diagnosis. JAMA Netw Open. 2021;4(6):e2115352&#x2013;e2115352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8226421</ArticleId><ArticleId IdType="pubmed">34165581</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol L. Long COVID: understanding the neurological effects. Lancet Neurol. 2020;19:471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7969137</ArticleId><ArticleId IdType="pubmed">33743226</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Xu E, Al-Aly Z. Kidney outcomes in long COVID. J Am Soc Nephrol. 2021;32(11):2851&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8806085</ArticleId><ArticleId IdType="pubmed">34470828</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S. et al. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol. 2021;32(1):151&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894657</ArticleId><ArticleId IdType="pubmed">32883700</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Bunker CB, Ciurtin C, Porter JC, Chambers RC, Papdopoulou C. et al. Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. Lancet Infect Dis. 2021;21(7):912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221732</ArticleId><ArticleId IdType="pubmed">33705725</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon DE, Gallman AE, Hruza GJ, Rosenbach M, Lipoff JB, Desai SR. et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis. 2021;21(3):313&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836995</ArticleId><ArticleId IdType="pubmed">33460566</ArticleId></ArticleIdList></Reference><Reference><Citation>Natalello G, De Luca G, Gigante L, Campochiaro C, De Lorenzis E, Verardi L. et al. Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. Microvasc Res. 2021;133:104071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494493</ArticleId><ArticleId IdType="pubmed">32949574</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H. et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Hong K, Gomez Gomez RE, Kim S, Chun BC. Lack of evidence of COVID-19 being a risk factor of alopecia areata: results of a national cohort study in South Korea. Front Med. 2021. 1805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8550157</ArticleId><ArticleId IdType="pubmed">34722594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ipsen C, van Veldhoven M, Kirchner K, Hansen JP. Six Key Advantages and Disadvantages of Working from Home in Europe during COVID-19. Int J Environ Res Public Health. 2021. 18(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7917590</ArticleId><ArticleId IdType="pubmed">33668505</ArticleId></ArticleIdList></Reference><Reference><Citation>Stecu&#x142;a K, Wolniak R. Advantages and Disadvantages of E-Learning Innovations during COVID-19 Pandemic in Higher Education in Poland. J Open Innov Technol Mark Complex. 2022. 8(3)</Citation></Reference><Reference><Citation>Mubaraki AA, Alrabie AD, Sibyani AK, Aljuaid RS, Bajaber AS, Mubaraki MA. Advantages and disadvantages of telemedicine during the COVID-19 pandemic era among physicians in Taif, Saudi Arabia. Saudi Med J. 2021 Jan;42(1):110&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989314</ArticleId><ArticleId IdType="pubmed">33399180</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyah Y, Benjelloun M, Lairini S, Lahrichi A. COVID-19 Impact on Public Health, Environment, Human Psychology, Global Socioeconomy, and Education. Piantino Ferreira AJ, editor. Sci World J. 2022 Jan 11;2022:5578284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767375</ArticleId><ArticleId IdType="pubmed">35069037</ArticleId></ArticleIdList></Reference><Reference><Citation>Radu MC, Schnakovszky C, Herghelegiu E, Ciubotariu VA, Cristea I. The Impact of the COVID-19 Pandemic on the Quality of Educational Process: A Student Survey. Int J Environ Res Public Health. 2020. 17(21)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660608</ArticleId><ArticleId IdType="pubmed">33114192</ArticleId></ArticleIdList></Reference><Reference><Citation>Sholukh AM, Fiore-Gartland A, Ford ES, Miner MD, Hou YJ, Tse LV. et al. Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays. J Clin Microbiol. 2021;59(10):e00527&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451402</ArticleId><ArticleId IdType="pubmed">34288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869748</ArticleId><ArticleId IdType="pubmed">33592168</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA, Cutler M, Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. BioRxiv. 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33558724</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. BioRxiv. 2021. pp. 2001&#x2013;21.</Citation></Reference><Reference><Citation>Khan A, Zia T, Suleman M, Khan T, Ali SS, Abbasi AA. et al. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data. J Cell Physiol. 2021;236(10):7045&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251074</ArticleId><ArticleId IdType="pubmed">33755190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Garc&#xed;a L, Espinel MA, Abreu M, Gonz&#xe1;lez-Alba JM, Gij&#xf3;n D, McGee A. et al. Emergence and spread of b. 1.1. 7 lineage in primary care and clinical impact in the morbi-mortality among hospitalized patients in madrid, spain. Microorganisms. 2021;9(7):1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8307589</ArticleId><ArticleId IdType="pubmed">34361951</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. Could new COVID variants undermine vaccines?. Labs scramble to find out. Nature. 2021;589(7841):177&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33432212</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA. et al. Effectiveness of mRNA Covid-19 vaccine among US health care personnel. N Engl J Med. 2021;385(25):e90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482809</ArticleId><ArticleId IdType="pubmed">34551224</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G. et al. Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. Biochem Biophys Res Commun. 2021;538:88&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836704</ArticleId><ArticleId IdType="pubmed">33199021</ArticleId></ArticleIdList></Reference><Reference><Citation>Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28(2):626&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818063</ArticleId><ArticleId IdType="pubmed">33479399</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. elife. 2020;9:e61312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratev F. N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human-derived antibody: a free energy of perturbation retrospective study. J Chem Inf Model. 2021;61(12):6079&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">34806876</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A. LVHN Scholarly Work s. N Engl J Med. 2020;383(27):2603&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Doggrell SA. Do we need bamlanivimab? Is etesevimab a key to treating Covid-19? Expert Opin Biol Ther. 2021;21(11):1359&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8500303</ArticleId><ArticleId IdType="pubmed">34555986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Poorbaugh J, Dougan M, Chen P, Gottlieb RL, Huhn G, Endogenous antibody responses to SARS-CoV-2 in patients with mild or moderate COVID-19 who received bamlanivimab alone or bamlanivimab and etesevimab together. Front Immunol. 2021. 5225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8697104</ArticleId><ArticleId IdType="pubmed">34956222</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaspe RC, Loureiro CL, Sulbaran Y, Moros ZC, D'Angelo P, Rodr&#xed;guez L. et al. Introduction and rapid dissemination of SARS-CoV-2 Gamma Variant of Concern in Venezuela. Infect Genet Evol. 2021;96:105147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8596652</ArticleId><ArticleId IdType="pubmed">34800714</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes BF, Corey L, Fernandes P, Gilbert PB, Hotez PJ, Rao S. et al. Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020;12(568):eabe0948.</Citation><ArticleIdList><ArticleId IdType="pubmed">33077678</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC Staff. Variants of the Virus | CDC [Internet] Centers for Disease Control and Prevention. 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvariants%2Fabout-variants.html.</Citation></Reference><Reference><Citation>Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP. et al. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. J Autoimmun. 2021;124:102715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354793</ArticleId><ArticleId IdType="pubmed">34399188</ArticleId></ArticleIdList></Reference><Reference><Citation>Katella K. Omicron, Delta, Alpha, and More: What To Know About the Coronavirus Variants [Internet] Yale Medicine: Family Health. 2021. p. 1-7. Available from: https://www.yalemedicine.org/news/covid-19-variants-of-concern-omicron.</Citation></Reference><Reference><Citation>Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H. et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B. 1.617. 2 (Delta) variant&#x2014;National Healthcare Safety Network, March 1-August. Morb Mortal Wkly Rep. 2021;70(34):1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389386</ArticleId><ArticleId IdType="pubmed">34437519</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19(8):810&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32704139</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleem A, AB AS, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19) 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Agwa SHA, Kamel MM, Elghazaly H, Abd Elsamee AM, Hafez H, Girgis SA. et al. Association between interferon-lambda-3 rs12979860, TLL1 rs17047200 and DDR1 rs4618569 variant polymorphisms with the course and outcome of SARS-CoV-2 patients. Genes. 2021;12(6):830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8230293</ArticleId><ArticleId IdType="pubmed">34071309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferr&#xe9; VM, Peiffer-Smadja N, Visseaux B, Descamps D, Ghosn J, Charpentier C. Omicron SARS-CoV-2 variant: What we know and what we don't. Anaesth Crit Care Pain Med. 2022;41(1):100998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8660660</ArticleId><ArticleId IdType="pubmed">34902630</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SI, Madzorera VS, Spencer H, Manamela NP, van der Mescht MA, Lambson BE. et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe. 2022;30(6):880&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8947963</ArticleId><ArticleId IdType="pubmed">35436444</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L. et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant. N Engl J Med. 2021;384(20):1899&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091623</ArticleId><ArticleId IdType="pubmed">33951374</ArticleId></ArticleIdList></Reference><Reference><Citation>MOH I. Corona - Control Panel [Internet] 2020. Available from: https://datadashboard.health.gov.il/COVID-19/general.</Citation></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern. MedRxiv. 2021. pp. 2012&#x2013;21.</Citation></Reference><Reference><Citation>Parums DV. Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2. Med Sci Monit Int Med J Exp Clin Res. 2023 Sep 1;29:e942244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10478578</ArticleId><ArticleId IdType="pubmed">37654205</ArticleId></ArticleIdList></Reference><Reference><Citation>China is bracing for a massive new wave of COVID cases.</Citation></Reference><Reference><Citation>WHO. COVID-19 Epidemiological Update [Internet] [cited. 2023. Dec 6]. Available from: https://www.who.int/publications/m/item/covid-19-epidemiological-update--24-november-2023.</Citation></Reference><Reference><Citation>Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">32227757</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf8;rzner K, Sheward DJ, Schmidt ST, Hanke L, Zimmermann J, McInerney G, Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. eBioMedicine [Internet]. 2021 Jan 1 [cited 2024 Jan 12];63. Available from: https://doi.org/10.1016/j.ebiom. 2020. 103197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808923</ArticleId><ArticleId IdType="pubmed">33422991</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan DS, Prasad R, Srivastava R, Jaggi M, Chauhan SC, Yallapu MM. Comprehensive review on current interventions, diagnostics, and nanotechnology perspectives against SARS-CoV-2. Bioconjug Chem. 2020;31(9):2021&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7425040</ArticleId><ArticleId IdType="pubmed">32680422</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines &#x2014; a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr 1;17(4):261&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilishvili T, Fleming-Dutra KE, Farrar JL, Gierke R, Mohr NM, Talan DA. et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel&#x2014;33 US sites, January-March 2021. Morb Mortal Wkly Rep. 2021;70(20):753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8136422</ArticleId><ArticleId IdType="pubmed">34014909</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 Oct 1;586(7830):594&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Foltran D, Delmas C, Flumian C, De Paoli P, Salvo F, Gautier S. et al. Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. Eur Heart J-Qual Care Clin Outcomes. 2022;8(2):99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8690190</ArticleId><ArticleId IdType="pubmed">34849667</ArticleId></ArticleIdList></Reference><Reference><Citation>Momin T, Kansagra K, Patel H, Sharma S, Sharma B, Patel J. et al. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine. 2021;38:101020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285262</ArticleId><ArticleId IdType="pubmed">34308319</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine?. A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21(2):e26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837315</ArticleId><ArticleId IdType="pubmed">33125914</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol. 2007;18(6):546&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2245896</ArticleId><ArticleId IdType="pubmed">18063357</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J&amp;. Johnson &amp; Johnson COVID-19 Vaccine Authorized by U [Internet] Johnson &amp; Johnson Services, Inc. 2021. Available from: https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic.</Citation></Reference><Reference><Citation>Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020;396(10249):479&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836858</ArticleId><ArticleId IdType="pubmed">32702299</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Putter JS. Immunotherapy for COVID-19: Evolving treatment of viral infection and associated adverse immunological reactions. Transfus Apher Sci. 2021;60(2):103093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7881713</ArticleId><ArticleId IdType="pubmed">33610448</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Could mixing COVID vaccines bolster immune response. Nature. 2021;590(7846):375&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33547431</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;396(10249):467&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445431</ArticleId><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27(9):1525&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440184</ArticleId><ArticleId IdType="pubmed">34262158</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ. et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. The Lancet. 2021;398(10303):856&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8346248</ArticleId><ArticleId IdType="pubmed">34370971</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity. 2010;33(4):451&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760154</ArticleId><ArticleId IdType="pubmed">21029957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196424</ArticleId><ArticleId IdType="pubmed">32413330</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorobjeva NV, Chernyak BV. NETosis: molecular mechanisms, role in physiology and pathology. Biochem Mosc. 2020;85:1178&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590568</ArticleId><ArticleId IdType="pubmed">33202203</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiam HR, Wong SL, Qiu R, Kittisopikul M, Vahabikashi A, Goldman AE. et al. NETosis proceeds by cytoskeleton and endomembrane disassembly and PAD4-mediated chromatin decondensation and nuclear envelope rupture. Proc Natl Acad Sci. 2020;117(13):7326&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132277</ArticleId><ArticleId IdType="pubmed">32170015</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: Is immunity the second function of chromatin? J Cell Biol. 2012 Sep 3;198(5):773&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3432757</ArticleId><ArticleId IdType="pubmed">22945932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott Jr W, Guda MR, Asuthkar S, Teluguakula N, Prasad DVR, Tsung AJ. et al. PAD inhibitors as a potential treatment for SARS-CoV-2 immunothrombosis. Biomedicines. 2021;9(12):1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8698348</ArticleId><ArticleId IdType="pubmed">34944683</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Front Immunol. 2020. 827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P. et al. Synergism of TNF-&#x3b1; and IFN-&#x3b3; triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021;184(1):149&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674074</ArticleId><ArticleId IdType="pubmed">33278357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P. et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020 Dec 4;5(1):283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7714896</ArticleId><ArticleId IdType="pubmed">33277466</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines. 2021;9(2):147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7918810</ArticleId><ArticleId IdType="pubmed">33673048</ArticleId></ArticleIdList></Reference><Reference><Citation>Laczk&#xf3; D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT. et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53(4):724&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392193</ArticleId><ArticleId IdType="pubmed">32783919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W, Zhang X, Drelich A, Shi J, Hsu JC, Luchsinger L. et al. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 2020;30(10):932&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403570</ArticleId><ArticleId IdType="pubmed">32759966</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S. et al. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2021;11(7):136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8323747</ArticleId><ArticleId IdType="pubmed">34330895</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhu M, Murphy EA, Sukhu AC, Yee J, Singh S, Eng D. et al. Antibody response to coronavirus disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into cord blood. Obstet Gynecol. 2021;138(2):278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8288193</ArticleId><ArticleId IdType="pubmed">33910219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nace DA, Kip KE, Mellors JW, Palmer OMP, Shurin MR, Mulvey K. et al. Antibody responses after mRNA-based COVID-19 vaccination in residential older adults: implications for reopening. J Am Med Dir Assoc. 2021;22(8):1593&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8196346</ArticleId><ArticleId IdType="pubmed">34129831</ArticleId></ArticleIdList></Reference><Reference><Citation>Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P. et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021;11(8):138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8327056</ArticleId><ArticleId IdType="pubmed">34341335</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinuesa CG, Linterman MA, Yu D, MacLennan ICM. Follicular helper T cells. Annu Rev Immunol. 2016;34:335&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">26907215</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A, Di Lauria N, Maggi L, Salvati L, Vanni A, Capone M, First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J Clin Invest. 2021. 131(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8203460</ArticleId><ArticleId IdType="pubmed">33939647</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A, Maggi L, Capone M, Vanni A, Spinicci M, Salvati L. et al. Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals. Clin Transl Immunol. 2021;10(5):e1281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8101693</ArticleId><ArticleId IdType="pubmed">33976879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti F, Cannatelli R, Benucci M, Carmagnola S, Clementi E, Danelli P. et al. How to manage COVID-19 vaccination in immune-mediated inflammatory diseases: an expert opinion by IMIDs study group. Front Immunol. 2021;12:656362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8082137</ArticleId><ArticleId IdType="pubmed">33936084</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Torre A, Bueno-Garc&#xed;a E, L&#xf3;pez-Mart&#xed;nez R, Rioseras B, Moro-Garc&#xed;a MA, Alonso-Alvarez S. et al. Surviving older patients show preserved cellular and humoral immunological memory several months after SARS-CoV-2 infection. J Gerontol Ser A. 2022;77(1):33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406858</ArticleId><ArticleId IdType="pubmed">34252180</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M. et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80(10):1339&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219484</ArticleId><ArticleId IdType="pubmed">34035003</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B. et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) The Lancet. 2021;398(10304):981&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409975</ArticleId><ArticleId IdType="pubmed">34480858</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM. et al. Interim results of a phase 1-2a trial of Ad26. COV2. S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821985</ArticleId><ArticleId IdType="pubmed">33440088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XR, Leung BP, Ng CYL, Tan JWL, Chan GYL, Loh CM. et al. Pseudo-anaphylactic reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis post Pfizer BNT162b2 vaccination. Vaccines. 2021;9(9):974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8471482</ArticleId><ArticleId IdType="pubmed">34579211</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf8;lb&#xf8;ll S&#xf8;rensen AL, Rolland M, Hartmann J, Harboe ZB, Roed C, Jensen T&#xd8;. et al. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2. Blood Adv. 2021;5(12):2569&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219289</ArticleId><ArticleId IdType="pubmed">34137813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PR, Mangion SA, Benger M, Stanton BR, Czuprynska J, Arya R. et al. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination-A report of two UK cases. Brain Behav Immun. 2021;95:514&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056834</ArticleId><ArticleId IdType="pubmed">33857630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamprinou M, Sachinidis A, Stamoula E, Vavilis T, Papazisis G. COVID-19 vaccines adverse events: potential molecular mechanisms. Immunol Res. 2023 Jun 1;71(3):356&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9821369</ArticleId><ArticleId IdType="pubmed">36607502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>